trapezoid glp-1 glp 1 use tripled among non-diabetics, reaching $5.8B in 2022 and metabolic wellness. GLP-1 Medications for Weight Loss:

These figures come from veterinary-derived and clinic sources, not human trials

There is currently no established causal link between tirzepatide and erectile dysfunction based on clinical trial data and post-marketing surveillance

BYETTA (exenatide) injection

These users report appreciating treatment benefits while active but watching improvements gradually fade over months post-discontinuation, with timeline showing first 2 months maintaining most benefits creating initial optimism, months 2-4 showing noticeable decline returning toward baseline, months 4-8 continuing regression approaching pre-treatment status, and stabilization occurring 60-80% back toward original baseline with only modest long-term improvement retention